Co-Diagnostics, Inc. (CODX): Price and Financial Metrics
CODX Price/Volume Stats
| Current price | $1.05 | 52-week high | $3.84 |
| Prev. close | $1.05 | 52-week low | $0.98 |
| Day low | $1.03 | Volume | 92,900 |
| Day high | $1.11 | Avg. volume | 122,079 |
| 50-day MA | $1.29 | Dividend yield | N/A |
| 200-day MA | $1.83 | Market Cap | 32.33M |
CODX Stock Price Chart Interactive Chart >
CODX POWR Grades
- CODX scores best on the Value dimension, with a Value rank ahead of 55.54% of US stocks.
- CODX's strongest trending metric is Value; it's been moving down over the last 179 days.
- CODX's current lowest rank is in the Growth metric (where it is better than 3.23% of US stocks).
CODX Stock Summary
- With a year-over-year growth in debt of 560.43%, CO-DIAGNOSTICS INC's debt growth rate surpasses 97.76% of about US stocks.
- Revenue growth over the past 12 months for CO-DIAGNOSTICS INC comes in at -90.67%, a number that bests merely 1.43% of the US stocks we're tracking.
- CO-DIAGNOSTICS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 36.36%, greater than the shareholder yield of 94.9% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to CO-DIAGNOSTICS INC are WOLF, KNSA, ONDS, DZSI, and QLGN.
- CODX's SEC filings can be seen here. And to visit CO-DIAGNOSTICS INC's official web site, go to www.codiagnostics.com.
CODX Valuation Summary
- CODX's price/sales ratio is 4.8; this is 152.63% higher than that of the median Healthcare stock.
- CODX's price/sales ratio has moved NA NA over the prior 75 months.
Below are key valuation metrics over time for CODX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CODX | 2023-09-18 | 4.8 | 0.3 | -0.9 | -0.5 |
| CODX | 2023-09-15 | 4.9 | 0.3 | -0.9 | -0.5 |
| CODX | 2023-09-14 | 5.3 | 0.4 | -1.0 | -0.6 |
| CODX | 2023-09-13 | 5.2 | 0.4 | -1.0 | -0.6 |
| CODX | 2023-09-12 | 5.1 | 0.4 | -1.0 | -0.6 |
| CODX | 2023-09-11 | 5.1 | 0.4 | -1.0 | -0.6 |
CODX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CODX has a Quality Grade of B, ranking ahead of 88% of graded US stocks.
- CODX's asset turnover comes in at 1.285 -- ranking 10th of 186 Medical Equipment stocks.
- ALGN, IART, and XENT are the stocks whose asset turnover ratios are most correlated with CODX.
The table below shows CODX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 1.285 | 0.835 | 2.189 |
| 2021-03-31 | 1.529 | 0.792 | 2.398 |
| 2020-12-31 | 1.631 | 0.777 | 2.360 |
| 2020-09-30 | 1.671 | 0.740 | 2.026 |
| 2020-06-30 | 1.636 | 0.746 | 2.230 |
| 2020-06-30 | 1.636 | 0.654 | 1.725 |
CODX Price Target
For more insight on analysts targets of CODX, see our CODX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $22.50 | Average Broker Recommendation | 1.67 (Moderate Buy) |
Co-Diagnostics, Inc. (CODX) Company Bio
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
Latest CODX News From Around the Web
Below are the latest news stories about CO-DIAGNOSTICS INC that investors may wish to consider to help them evaluate CODX as an investment opportunity.
Co-Diagnostics, Inc. to Participate in 6th ACTC Conference in Skiathos, GreeceCo-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be hosting a booth and presenting at the 6th Advances in Circulating Tumor Cells ("ACTC") conference held this week in Skiathos, Greece. |
Co-Diagnostics, Inc. to Participate in Gilmartin Group Annual Emerging Growth Showcase on Sept 21Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the Gilmartin Group Annual Emerging Growth Showcase. |
Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the H.C. Wainwright & Co. 25th Annual Global Investment Conference, being held virtually and in-person on September 11-13 in New York City, New York. |
Co-Diagnostics, Inc. Appoints Chief Regulatory Affairs OfficerCo-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Ivory Chang as the Company's Chief Regulatory Affairs Officer. |
Co-Diagnostics, Inc. to Present at 15th Next Generation Dx Summit in Washington, D.C.Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be sponsoring, presenting and hosting a booth at the 15th Annual Next Generation Dx Summit, held virtually and in-person in Washington, D.C. on August 21-23, 2023. |
CODX Price Returns
| 1-mo | -13.93% |
| 3-mo | -4.55% |
| 6-mo | -25.00% |
| 1-year | -65.23% |
| 3-year | -92.19% |
| 5-year | -60.67% |
| YTD | -58.33% |
| 2022 | -71.78% |
| 2021 | -3.98% |
| 2020 | 938.87% |
| 2019 | -39.92% |
| 2018 | -43.56% |
Continue Researching CODX
Want to see what other sources are saying about Co-Diagnostics Inc's financials and stock price? Try the links below:Co-Diagnostics Inc (CODX) Stock Price | Nasdaq
Co-Diagnostics Inc (CODX) Stock Quote, History and News - Yahoo Finance
Co-Diagnostics Inc (CODX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...